HighTower Advisors
SPRY icon

HighTower Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

HighTower Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$206K Buy
25,689
+276
+1% +$2.37K ﹤0.01% 3522
2026
Q1 		$204K Sell
25,413
-1,116
-4% -$10.7K ﹤0.01% 3468
2025
Q4 		$309K Buy
26,529
+199
+0.8% +$1.94K ﹤0.01% 3023
2025
Q3 		$265K Buy
26,330
+220
+0.8% +$3.16K ﹤0.01% 3148
2025
Q2 		$456K Sell
26,110
-35
-0.1% -$505 ﹤0.01% 2604
2025
Q1 		$329K Sell
26,145
-965
-4% -$11.6K ﹤0.01% 2784
2024
Q4 		$286K Sell
27,110
-1,200
-4% -$16.8K ﹤0.01% 2921
2024
Q3 		$411K Buy
28,310
+4,369
+18% +$52K ﹤0.01% 2552
2024
Q2 		$204K Sell
23,941
-853
-3% -$7.57K ﹤0.01% 3007
2024
Q1 		$253K Buy
24,794
+9,655
+64% +$72K ﹤0.01% 2811
2023
Q4 		$82K Sell
15,139
-7,640
-34% -$33.5K ﹤0.01% 3237
2023
Q3 		$87K Buy
22,779
+1,779
+8% +$11.7K ﹤0.01% 3129
2023
Q2 		$141K Buy
21,000
+10,000
+91% +$66.7K ﹤0.01% 2988
2023
Q1 		$72K Buy
+11,000
New +$84.5K ﹤0.01% 2996

Other funds holding SPRY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
PCML
Pavaki Capital Management LLC Pueblo, Colorado $287M AUM
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
ELI
Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.36B AUM 25.57% 1-Year Est. Return

HighTower Advisors's SPRY Position: Q2 2026 in Review

HighTower Advisors increased its ARS Pharmaceuticals (SPRY) stake by 1.1% in Q2 2026, buying an estimated $2.37K and bringing the position to 25,689 shares worth $206K. The position accounts for ﹤0.01% of the portfolio, ranked #3522.

HighTower Advisors first reported a position in SPRY in Q1 2023 and has held it in 14 quarters since. The position peaked at $456K in Q2 2025. 68 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • HighTower Advisors held 25,689 shares of ARS Pharmaceuticals worth $206K as of Q2 2026.
  • HighTower Advisors bought 276 ARS Pharmaceuticals shares in Q2 2026, an estimated $2.37K.
  • ARS Pharmaceuticals made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3522 holding.
  • HighTower Advisors first reported a position in ARS Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • HighTower Advisors's ARS Pharmaceuticals position peaked at $456K in Q2 2025.
  • 68 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.